The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Strong Support for Treat-to-Target Strategy in RA Patients

Strong Support for Treat-to-Target Strategy in RA Patients

March 16, 2020 • By Megan Brooks

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data.

You Might Also Like
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes
  • Treat-to-Target Strategy Evaluated for Fibromyalgia Care

“The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T, immediately results in a higher likelihood of remission at the next visit, three months later (the longitudinal interpretation of a T2T-strategy),” Dr. Sofia Ramiro of Leiden University Medical Center, Netherlands, tells Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Moreover, we have for the first time shown that following T2T is also efficacious in patients with established RA, while previous studies focused on the effect of T2T in patients with early RA,” she says.

The study was published in Annals of the Rheumatic Diseases.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The findings are based on 571 RA patients from the RA BIODAM (BIOmarkers of joint DAMage) cohort who were starting or changing conventional synthetic or biological disease-modifying anti-rheumatic drugs. The patients had RA for an average of 6.5 years and were assessed every three months for two years. The total number of visits was 4,356.

At each visit, it was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44 <1.6) as the target. Sustained T2T was defined as T2T followed in at least two consecutive visits. The main outcome was the achievement of DAS44 remission at the subsequent three-month visit.

The correct application of T2T was found in 59% of patient visits. T2T (vs. no T2T) did not yield a higher likelihood of DAS44 remission three months later, but sustained T2T was associated with an increased likelihood of achieving DAS44 remission (odds ratio: 1.19; 95% confidence interval: 1.03–1.39).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Similar results were seen with 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR) remission. For more stringent definitions—Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission—T2T was consistently and significantly associated with remission, and sustained T2T had a more pronounced effect on remission.

“Randomized controlled trials have demonstrated the efficacy of T2T approaches in RA,” Dr. Ramiro tells Reuters Health. The current analysis, she said, provides “real-life data from cohorts without strict protocol specifications regarding choice of treatment” and supports the value of T2T in clinical practice.

“Rheumatologists should be encouraged to follow a T2T-strategy to contribute to the achievement of higher rates of remission for their patients,” Dr. Ramiro says.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Rheumatoid Arthritis (RA), Treat-to-Target

You Might Also Like:
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes
  • Treat-to-Target Strategy Evaluated for Fibromyalgia Care
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.